Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: juneau_boy who wrote (546)	3/17/2000 9:55:00 AM
From: nigel bates	Respond to of 1834

>>Any concern over market cap per employee in this market?<< No. nig

To: juneau_boy who wrote (546)	3/17/2000 11:35:00 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 1834

>> Any concern over market cap per employee in this market? << No.

To: juneau_boy who wrote (546)	3/22/2000 10:35:00 AM
From: aknahow	Read Replies (2) \| Respond to of 1834

No concern either, but interested in who proposed this as measure of anything and what profitable use was made of this theory? Oil companies have a very high cap per employee, and while biotechs are obviously different over staffing would lead to a lower, "better" ratio. This does not mean I would consider a higher ratio as good, but rather that the concept is meaningless as a measure of value for biotechs. But I am interested in seeing any study which indicates I am wrong about this.